Phase Ii Study Of Ipilimumab, Nivolumab, And Panitumumab In Patients With Kras/Nras/Braf Wild-Type (Wt) Microsatellite Stable (Mss) Metastatic Colorectal Cancer (Mcrc).

Michael Sangmin Lee,Patrick J. Loehrer,Iman Imanirad,Stacey Cohen,Kristen Keon Ciombor,Dominic T. Moore,Cheryl Ann Carlson,Hanna Kelly Sanoff,Autumn Jackson McRee

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 27|浏览6

暂无评分

摘要

7Background: Panitumumab is a monoclonal antibody (mAb) targeting the epidermal growth factor receptor (EGFR) and is a standard therapy in KRAS/NRAS/BRAF WT mCRC. Preclinical data shows that anti-E...

查看译文

关键词

colorectal cancer,microsatellite,panitumumab,nivolumab,wild-type

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要